Prof François Duhoux meets Prof Sara Hurvitz: The ELEVATE study

Prof Sara Hurvitz, medical oncologist and clinical research leader at Fred Hutchinson Cancer Center in Seattle, briefly discusses with Prof François Duhoux, medical oncologist and head of clinic of the department of oncology at the Cliniques Universitaires in Brussels, on a poster in which the ELEVATE study is introduced.  

The ELEVATE trial, an umbrella trial involving elacestrant, aims to explore the safety and early activity of combining elacestrant with various agents, including everolimus, ribociclib, and palbociclib. Since elacestrant demonstrated superiority over standard-of-care endocrine therapy in the EMERALD trial, particularly benefiting patients with ESR1-mutations, combining it with targeted therapies represents a logical progression. The goal is to enhance the efficacy of elacestrant. The results from ELEVATE will contribute valuable insights and may guide the design of larger studies.

Reference:

Hope R.. et al., ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)-   SABCS 2023, #P02-05-04